Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer - Drug Trials For Money

Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Colorectal Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Metastatic Ovarian Carcinoma; Metastatic Renal Cell Carcinoma; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Platinum-Resistant Ovarian Carcinoma; Recurrent Melanoma; Recurrent Renal Cell Carcinoma; Refractory Melanoma; Refractory Renal Cell Carcinoma; Sarcoma; Stage IV Colorectal Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8
Interventions: Biological: Pembrolizumab; Biological: Ziv-Aflibercept
Sponsor: National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.